Deutsch

enlarged text

Lux Biosciences Reports on Pivotal Programs in Uveitis
and Corneal Transplant Rejection at ARVO Meeting

JERSEY CITY, N.J. (April 24, 2008): Lux Biosciences, Inc., a privately held biotechnology company specialized in the field of ophthalmic diseases, announced today that the company’s two lead product candidates, LX211 for the treatment of uveitis and LX201 for the prevention of corneal transplant rejection, will be highlighted in multiple presentations at the 2008 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The international meeting is being held from April 27 – May 1 in Fort Lauderdale, Florida.

“We have made major progress in the recruitment of both the LUMINATE and LUCIDA programs and are likely
to reach important recruitment milestones in mid-year. We credit our investigators for this timely enrollment,
and appreciate their strong interest and high motivation,” said Ulrich Grau, Ph.D., Lux Biosciences President and Chief Executive Officer. “Both programs address high medical needs, and are potentially important firsts:
LX211 is the first steroid sparing agent that is being developed towards approval in sight-threatening
non-infectious uveitis, and LX201 is the first drug under development for the prevention of rejections in
cornea transplant patients.”

LX211, the oral form of a next generation calcineurin inhibitor (voclosporin), which Lux Biosciences licensed for ophthalmic indications from Isotechnika, Inc. in 2006, is being featured in a poster presentation on April 28. The poster describes the design of the ongoing pivotal trial program in different types of sight-threatening non-infectious uveitis, by clinical investigator J.T. Rosenbaum, M.D. from the Casey Eye Institute-OHSU, Portland, Oregon, on behalf of the international LUMINATE Study Group. Also to be presented by Lux Biosciences and collaborators from the National Eye Institute is a poster on April 30 demonstrating LX211’s ability to suppress anti-CD3 activated human T cell proliferation and to successfully treat experimental autoimmune uveitis in rats.

On April 28 Alan Sugar, MD, from the University of Michigan-Kellogg Eye Center will give an oral presentation on behalf of the international LUCIDA Study Group discussing the design of the pivotal trial program for LX201. LX201 is a novel cyclosporine A-eluting, episcleral implant, and is being studied for the prevention of corneal allograft rejection or graft failure in patients at high risk. The LUCIDA studies are the first prospective, randomized, placebo-controlled trials in this indication. LX201 is also the subject of a poster presentation on April 28 by researchers from Lux Biosciences and collaborators at North Carolina State University, the University of Missouri, Sinclair Research Center and Contract Kinetica detailing the results of a preclinical safety and pharmacokinetic study that support the use of the implant in cornea transplant patients.


About Lux Biosciences
Lux Biosciences, Inc. is a privately held biotechnology company focused on ophthalmic diseases. The company has a staged product portfolio of potentially first-in-class therapies distinguished by their short-term path to commercialization and potential to generate high revenue growth. The portfolio includes:

• Two Phase 3 clinical-stage projects including: i) LX211, the oral formulation of a next-generation calcineurin inhibitor (voclosporin) developed as steroid sparing therapy for the treatment of non-infectious uveitis, and ii) LX201, a silicone matrix ocular (episcleral) implant that steadily releases therapeutic doses of cyclosporine A locally to the eye for the prevention of rejection in cornea transplant recipients. Both the LUMINATE pivotal clinical program for LX211 for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007 and include sites in North America, Europe and India.

• LX214, a novel topical eye drop formulation currently in IND-enabling studies with a target date for entry into the clinic in mid 2008. LX214 is based on Lux’ proprietary next-generation calcineurin inhibitor and is targeted towards other chronic inflammatory diseases of the eye, most notably dry eye syndrome, blepharitis and atopic keratoconjunctivitis.

• Several earlier stage projects based on proprietary product-enabling bio-erodible polymer technologies that facilitate targeted and sustained delivery of molecules to the eye.

For more information on Lux Biosciences, please visit the company’s website at www.luxbio.com.

###

CONTACTS:

Lux Biosciences, Inc.
Ulrich Grau, Ph.D.
+1 201 946 0221
Ulrich.grau@luxbio.com

Kureczka/Martin Associates (media)
Joan Kureczka
+1 415-821-2413
Jkureczka@comcast.net